AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

BACKGROUND: For estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC), the current standard first-line treatment includes an aromatase inhibitor in combination with a cyclin-dependent kinase 4/6 inhibitor. When resistance occurs, ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardia, Aditya, Cortes, Javier, Hurvitz, Sara A., Delaloge, Suzette, Iwata, Hiroji, Shao, Zhi-Ming, Kanagavel, Dheepak, Cohen, Patrick, Liu, Qianying, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, O’Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928355/
https://www.ncbi.nlm.nih.gov/pubmed/35309087
http://dx.doi.org/10.1177/17588359221083956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928355/
https://www.ncbi.nlm.nih.gov/pubmed/35309087
http://dx.doi.org/10.1177/17588359221083956

Ejemplares similares